BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Plethora Solutions Holdings 



London  England    United Kingdom
Phone: n/a Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





 Company News
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation 7/29/2009 9:44:44 AM    More...
Plethora Solutions Holdings Sells Lead Drug Rights, Cuts Debt by 90% 5/26/2009 7:30:01 AM    More...
Sciele Pharma, Inc. (SCRX) And Plethora Solutions Holdings Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation 4/28/2009 9:26:58 AM    More...
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Completion of Patient Recruitment for Global Phase III Trial of PSD502 for Premature Ejaculation 2/18/2009 10:12:20 AM    More...
Sciele Pharma, Inc. (SCRX) and Plethora Solutions Holdings Announce Final Analysis of PSD502 for Premature Ejaculation; All Primary and Secondary Endpoints Met in Phase III Pivotal Trial 12/8/2008 12:39:55 PM    More...
Plethora Solutions Holdings Release: New Study Confirms the Role of ErecAid(R) as Supplemental First Line Treatment for Erectile Dysfunction 11/18/2008 8:17:28 AM    More...
Sciele Pharma, Inc. (SCRX) Announces That Plethora Solutions Holdings Has Completed European Phase III Trial of PSD502 for Premature Ejaculation 10/1/2008 9:14:11 AM    More...
Plethora Solutions Holdings and Paul Capital Healthcare Sign a $25M Revenue Interest Financing Agreement 4/1/2008 7:11:29 AM    More...
Sciele Pharma, Inc. (SCRX) Enters Into Exclusive License Agreement with Plethora Solutions Limited to Market PSD502 for the Treatment of Premature Ejaculation; Sciele to Purchase $7 Million Stake in Plethora 5/24/2007 9:21:19 AM    More...
Inyx, Inc. Signs Deal With Plethora Solutions Holdings To Produce Novel HFA Aerosol Indicated For The Treatment Of Premature Ejaculation For Clinical Trial In The United States 11/2/2006 4:11:27 PM    More...
12

//-->